Bio-Path Holdings, Inc. (BPTH) is making waves in the stock market today, with its shares experiencing a dramatic rise. The company’s strong performance is fueled by exciting news across several fronts.
Firstly, Bio-Path has initiated a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases. This program marks a significant milestone for the company as it represents the first application of its innovative DNAbilize technology outside of cancer treatments. The company plans to commence preclinical studies in the fourth quarter of 2024, aiming to gain crucial insights into the mechanism and efficacy of BP1001-A in enhancing insulin sensitivity. These studies are expected to shed light on BP1001-A’s potential therapeutic benefits for obesity and Type 2 diabetes.
Adding to the positive momentum, Bio-Path has announced the completion of enrollment in the third dosing cohort of its ongoing Phase 1/1b clinical trial evaluating BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients, including those resistant to venetoclax. Venclexta (venetoclax), developed by AbbVie Inc (ABBV) and Roche Holdings AG’s (RHHBY) Genentech, is a current standard-of-care treatment for AML.
Bio-Path believes that BP1002, by targeting the key protein involved in venetoclax treatment at the mRNA level, has the potential to overcome and prevent certain mechanisms of resistance that can arise during venetoclax therapy.
In August, Bio-Path provided updates on its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients, reporting continued patient progress. The company also highlighted its ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia. Notably, this cohort enrolled more quickly than anticipated, completing within six weeks, which underscores the urgent need for new treatment options for these relapsed/refractory patients.
The market has reacted positively to these announcements, with BPTH stock soaring 51.50% to $1.30 during the premarket session. This significant surge highlights investors’ confidence in Bio-Path’s potential to develop groundbreaking treatments for a range of critical diseases.
